Outlook Therapeutics, Inc. granted stock options to purchase 150,000 shares of common stock to two new employees with an exercise price of $2.01 per share. The awards were given as an inducement for the employees to join the company. Outlook Therapeutics focuses on developing and commercializing ONS-5010/LYTENAVA™ to enhance the standard of care for bevacizumab in treating retinal diseases. LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for wet AMD. In the U.S., ONS-5010/LYTENAVA™ is still investigational and, if approved, would be the first ophthalmic formulation of bevacizumab for retinal indications.

Read more at GlobeNewswire: Outlook Therapeutics Announces New Employment Inducement